Gilead CEO: Remdesivir Priced ‘Significantly’ Below Value to Society
Sydney Otomancek2023-12-14T13:17:55-05:00July 1st, 2020|Categories: Featured, HEOR Feature, Industry News|Tags: COVID-19, Daniel O'Day, Gilead, Healtheconomics.com, HEOR, market access, Peter Bach, remdesivir|
Gilead CEO Daniel O'Day told STAT he's confident in the company's pricing decision for the COVID-19 drug remdesivir. "We spent [...]
Gilead Sets Price for Remdesivir
Sydney Otomancek2023-12-14T13:17:57-05:00June 30th, 2020|Categories: Featured, Industry News|Tags: COVID-19, Daniel O'Day, Gilead, market access, remdesivir|
Gilead announced it would charge between $2,340 and $3,120 for a 5-day course of its COVID-19 drug remdesivir, BioPharma Dive [...]
Receive essential insights, resources and content direct to your inbox!
Hit subscribe to stay informed!
Advertisement
Latest News
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Categories
Artificial Intelligence
Careers
Clinical Trials
Cost Effectiveness
Data Analytics & Syndicated Reports
Healthcare Financing
Health Databases
Health Equity
Health Policy
Health Tech Assessment
HEOR
Integrated Evidence Assessment & Planning
Market Access
Medical Affairs
Patient Outcomes & Engagement
Press Release
Pricing & Reimbursement
Real World Data
Real World Evidence
Value Assessment
Value Communication